Eli Lilly And Co vs UDR Inc. Common Stock — how do they compare? Eli Lilly And Co trades at $1,226 (market cap $1.04T), while UDR Inc. Common Stock trades at $33.9 (market cap $10.93B). The key difference: Eli Lilly And Co is far larger — about 95.2× UDR Inc. Common Stock's market cap, and UDR Inc. Common Stock pays the higher dividend (5.12%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and UDR Inc. Common Stock for 0 Days on average.
| LLY | UDR | |
|---|---|---|
Market Cap | $1.04T | $10.93B |
Volume | 1,843,375 | 2,607,837 |
Sector | Health | Real Estate |
52-Week High | $1.28K | $41.24 |
52-Week Low | $799.57 | $33.27 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.09T | $16.96B |
Dividend Yield | 0.59% | 5.12% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,211.40, up 2.43% today, with a bullish technical outlook and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights pipeline advancements in weight-loss drugs, including EloraTZP's promising trial results.
Outlook remains positive given dominant market position in obesity and diabetes treatments, with analyst consensus price target of $1,350 implying ~11% upside. Key risks include competitive pressures from Novo Nordisk and regulatory hurdles. Earnings growth and pipeline catalysts support further appreciation, though high valuations warrant monitoring.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →UDR, Inc. is a self-administered real estate investment trust that owns, operates, develops, and redevelops multifamily apartment communities across targeted US markets. The company generates income primarily through leasing apartment homes, with a portfolio concentrated in coastal and Sunbelt metropolitan areas.
Read more on UDR →